Bimekizumab Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Bimekizumab comprises 78 peer-reviewed publications across 15 journals, 21 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Psoriasis, Arthritis, Psoriatic, Spondylitis, Ankylosing, and Hidradenitis Suppurativa. Most recent publication: Bimekizumab efficacy using IHS4 outcomes in hidradenitis suppurativa: Results from BE HEARD I and II., J Eur Acad Dermatol Venereol, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials.
    van der Heijde D, Deodhar A, Baraliakos X, et al. · Ann Rheum Dis · 2023
    PubMed: PMID 36649967 · NCT03928704 (BE MOBILE 1) · Axial Spondyloarthritis
  2. Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial.
    Thaçi D, Vender R, de Rie MA, et al. · Br J Dermatol · 2023
    PubMed: PMID 36689515 · NCT03598790 (BE BRIGHT) · Psoriasis
  3. Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial.
    Strober B, Paul C, Blauvelt A, et al. · J Am Acad Dermatol · 2023
    PubMed: PMID 37182701 · NCT03536884 (BE RADIANT) · Psoriasis
  4. Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trials.
    Lebwohl M, Merola JF, Strober B, et al. · J Am Acad Dermatol · 2024
    PubMed: PMID 38588819 · NCT03536884 (BE RADIANT) · Psoriasis
  5. Psychometric validation and interpretation thresholds of the Hidradenitis Suppurativa Quality of Life (HiSQOL©) questionnaire using pooled data from the phase III BE HEARD I & II trials of bimekizumab in hidradenitis suppurativa.
    Kirby JS, Thorlacius L, Lambert J, et al. · Br J Dermatol · 2025
    PubMed: PMID 40172122 · NCT04242446 (BE HEARD I) · Hidradenitis Suppurativa
  6. Effect of bimekizumab on patient-reported disease impact in patients with psoriatic arthritis: 1-year results from two phase 3 studies.
    Gossec L, Orbai AM, de Wit M, et al. · Rheumatology (Oxford) · 2024
    PubMed: PMID 38754125 · NCT04009499 (BE VITAL) · Arthritis, Psoriatic
  7. Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials.
    Gordon KB, Langley RG, Warren RB, et al. · Br J Dermatol · 2024
    PubMed: PMID 37950894 · NCT03598790 (BE BRIGHT) · Psoriasis
  8. Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials.
    Brown MA, Rudwaleit M, van Gaalen FA, et al. · Ann Rheum Dis · 2024
    PubMed: PMID 38977276 · NCT04436640 (BE MOVING) · Spondylitis, Ankylosing

Primary-outcome results across pivotal trials

Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.

TrialIndicationPrimary endpointArmValue
NCT03370133
BE VIVID
PsoriasisPercentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 16
Week 16
Bimekizumab 320 mg Q4W (RS)85.0 percentage of participants
Placebo (RS)4.8 percentage of participants
Ustekinumab (RS)49.7 percentage of participants
NCT03370133
BE VIVID
PsoriasisPercentage of Participants With an Investigator's Global Assessment (IGA) (Clear or Almost Clear With at Least a 2-category Improvement From Baseline) Response at Week 16
Week 16
Bimekizumab 320 mg Q4W (RS)84.1 percentage of participants
Placebo (RS)4.8 percentage of participants
Ustekinumab (RS)53.4 percentage of participants
NCT03410992
BE READY
PsoriasisPercentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 16
At Week 16
Bimekizumab 320 mg Q4W (RS)90.8 percentage of participants
Placebo (RS)1.2 percentage of participants
NCT03410992
BE READY
PsoriasisPercentage of Participants With an Investigator's Global Assessment (IGA) Response at Week 16
At Week 16
Bimekizumab 320 mg Q4W (RS)92.6 percentage of participants
Placebo (RS)1.2 percentage of participants
NCT03412747
BE SURE
PsoriasisPercentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 16
Week 16
Adalimumab (RS)47.2 percentage of participants
Bimekizumab 320 mg Q4W + Bimekizumab 320 mg Q4W/Q8W (RS)86.2 percentage of participants
NCT03412747
BE SURE
PsoriasisPercentage of Participants With an Investigator's Global Assessment (IGA) Response (Clear or Almost Clear With at Least 2-Category Improvement Relative to Baseline) at Week 16
Week 16
Adalimumab (RS)57.2 percentage of participants
Bimekizumab 320 mg Q4W + Bimekizumab 320 mg Q4W/Q8W (RS)85.3 percentage of participants
NCT03536884
BE RADIANT
PsoriasisPercentage of Participants With a Psoriasis Area and Severity Index 100 (PASI100) Response at Week 16
Week 16
ITP: Bimekizumab (BKZ) 320 mg Q4W61.7 percentage of participants
ITP: Secukinumab 300 mg Q4W48.9 percentage of participants
NCT03598790
BE BRIGHT
PsoriasisNumber of Treatment Emergent Adverse Events (TEAEs) Adjusted by Duration of Subject Exposure to Investigational Medicinal Product (IMP)
From Baseline up to 165 weeks for each study participant not entering the OLE2 Period and up to 212 weeks for participants entering OLE2 Period
Cohort A: BKZ 320 mg Q4W179.68 no. of new events per 100 subject-years
Cohort A: BKZ 320 mg Q8W97.83 no. of new events per 100 subject-years
Cohort A: Group A BKZ 320 mg Q8W79.02 no. of new events per 100 subject-years
Cohort A: Group B BKZ 320 mg Q4W/Q8W73.78 no. of new events per 100 subject-years
Cohort A: Group B BKZ 320 mg Q8W77.11 no. of new events per 100 subject-years
Cohort B: EP BKZ Total328.25 no. of new events per 100 subject-years
Cohort B: GPP BKZ Total188.71 no. of new events per 100 subject-years
Cohort B: PSO BKZ Total244.08 no. of new events per 100 subject-years
NCT03766685PsoriasisPercentage of Participants Able to Self-administer Safe and Effective Injections Using the Bimekizumab-safety Syringe (SS)-1mL or the Bimekizumab-auto-injector (AI)-1mL at Week 8, After Training in Self-injection Technique
Week 8
Bimekizumab-SS-1mL 320 mg (FAS-s-1mL)100 percentage of participants
Bimekizumab -AI-1mL 320 mg (FAS-a-1mL)100 percentage of participants
NCT03766685PsoriasisPercentage of Participants Able to Self-administer Safe and Effective Injections Using the Bimekizumab-SS-2mL or the Bimekizumab-AI-2mL at Week 8, After Training in Self-injection Technique
Week 8
Bimekizumab-AI-2mL 320 mg (FAS-a-2mL)94.7 percentage of participants
Bimekizumab-SS-2mL 320 mg (FAS-s-2mL)100 percentage of participants
NCT03895203
BE OPTIMAL
Arthritis, PsoriaticPercentage of Participants With an American College of Rheumatology (ACR) 50 Response at Week 16
Week 16
ADA 40 mg Q2W45.7 percentage of participants
BKZ 160 mg Q4W43.9 percentage of participants
Placebo10.0 percentage of participants
NCT03896581
BE COMPLETE
Arthritis, PsoriaticPercentage of Participants With American College of Rheumatology 50 (ACR50) Response
From Baseline to Week 16
Bimekizumab 160mg43.4 percentage of participants
Placebo6.8 percentage of participants
NCT03928704
BE MOBILE 1
Axial SpondyloarthritisPercentage of Participants With Assessment of SpondyloArthritis International Society 40% Response Criteria (ASAS40) Response at Week 16
Week 16
Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population)33.3 percentage of participants
Bimekizumab 160 mg Q4W (up to Week 16) (Global Population)47.7 percentage of participants
Placebo (up to Week 16) (China Extension Population)27.3 percentage of participants
Placebo (up to Week 16) (Global Population)21.4 percentage of participants
NCT03928743
BE MOBILE 2
Spondylitis, AnkylosingPercentage of Participants With Assessment of SpondyloArthritis International Society 40% Response Criteria (ASAS40) Response at Week 16
Week 16
Bimekizumab 160 mg Q4W (up to Week 16)44.8 percentage of participants
Placebo (up to Week 16)22.5 percentage of participants
NCT04109976Arthritis, PsoriaticPercentage of Participants Able to Self-administer Safe and Effective Injections Using the Bimekizumab Safety Syringe (BKZ-SS) or the Bimekizumab Auto-injector (BKZ-AI) at Week 4
Week 4
BKZ-AI-1mL 160 mg Q4W100 percentage of participants
BKZ-SS-1mL 160 mg Q4W100 percentage of participants
NCT04242446
BE HEARD I
Hidradenitis SuppurativaPercentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) at Week 16
Week 16
BKZ Dosing Regimen 145.3 percentage of participants
BKZ Dosing Regimen 247.8 percentage of participants
Placebo28.7 percentage of participants
NCT04242498
BE HEARD II
Hidradenitis SuppurativaPercentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) at Week 16
Week 16
BKZ Dosing Regimen 153.8 percentage of participants
BKZ Dosing Regimen 252.0 percentage of participants
Placebo32.2 percentage of participants
NCT05020249—Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 16
Week 16
Bimekizumab 320 mg Q4W81.3 percentage of participants
Placebo0 percentage of participants
NCT05020249—Percentage of Participants With an Investigator's Global Assessment (IGA) 0/1 (Clear or Almost Clear With at Least 2-category Improvement From Baseline) Response at Week 16
Week 16
Bimekizumab 320 mg Q4W87.5 percentage of participants
Placebo0 percentage of participants
NCT06011733
BE SHINING
PsoriasisPercentage of Participants With Investigator´s Global Assessment (IGA) 0/1 Response at Week 16
Week 16
ITP: BKZ Dosage Regimen 192.0 percentage of participants
ITP: Placebo3.0 percentage of participants
NCT06011733
BE SHINING
PsoriasisPercentage of Participants With Psoriasis Area Severity Index 90 (PASI90) Response at Week 16
Week 16
ITP: BKZ Dosage Regimen 194.0 percentage of participants
ITP: Placebo3.0 percentage of participants

Publications by year

2016–2026: 78 publications.

2016
1
2020
3
2021
8
2022
7
2023
11
2024
18
2025
21
2026
9

Publications by indication

Psoriasis (33)

  • Bimekizumab long-term response in psoriasis: Mechanistic insights into efficacy level and durability.
    J Allergy Clin Immunol · 2026 · PMID 41580158 · NCT03370133
  • Bimekizumab efficacy in scalp, nail and palmoplantar psoriasis versus comparators and over 4 years.
    J Dermatolog Treat · 2026 · PMID 41800601 · NCT03536884
  • Bimekizumab Impact on Patient-Reported Outcomes in Plaque Psoriasis: 4-Year Results from BE SURE, BE VIVID, BE READY, and BE BRIGHT.
    Dermatol Ther (Heidelb) · 2026 · PMID 41359217 · NCT03410992
  • Three-Year Patient-Reported Outcomes From Bimekizumab for Plaque Psoriasis: The BE RADIANT Randomized Clinical Trial With Open-Label Extension.
    JAMA Dermatol · 2026 · PMID 41706476 · NCT03536884
  • Bimekizumab Efficacy in Psoriasis by Subgroups: Post Hoc Analysis of Phase 3/3b Clinical Trials.
    Dermatol Ther (Heidelb) · 2025 · PMID 41060492 · NCT03598790

Arthritis, Psoriatic (19)

  • Bimekizumab Efficacy and Safety in Patients with Psoriatic Arthritis with Substantial Skin and Nail Psoriasis to 1 Year.
    Dermatol Ther (Heidelb) · 2026 · PMID 41381988 · NCT04009499
  • Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison.
    Rheumatol Ther · 2026 · PMID 38446397 · NCT03896581
  • Bimekizumab safety and efficacy in patients with psoriatic arthritis: 3-year results from two phase 3 studies.
    Rheumatology (Oxford) · 2026 · PMID 41838419 · NCT03896581
  • Comparative Effectiveness of Bimekizumab and Risankizumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison.
    Rheumatol Ther · 2025 · PMID 39120849 · NCT04009499
  • Summary of Research: Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies.
    Rheumatol Ther · 2025 · PMID 40347389 · NCT03895203

Spondylitis, Ankylosing (12)

  • Bimekizumab longer-term safety profile in adult patients with axial spondyloarthritis or psoriatic arthritis: an updated analysis of six phase IIb/III clinical studies.
    RMD Open · 2026 · PMID 41807031 · NCT03355573
  • Sustained resolution of enthesitis and peripheral arthritis over 104 weeks with bimekizumab in axial spondyloarthritis.
    RMD Open · 2025 · PMID 41125403 · NCT04436640
  • Long-term safety of bimekizumab in adult patients with axial spondyloarthritis or psoriatic arthritis: pooled results from integrated phase IIb/III clinical studies.
    RMD Open · 2025 · PMID 40194794 · NCT04436640
  • Sustained improvements in spinal pain, morning stiffness, fatigue, sleep, physical function and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: 2-year results from two phase 3 studies.
    RMD Open · 2025 · PMID 41314667 · NCT03928743
  • Long-term safety and sustained efficacy of bimekizumab in patients with ankylosing spondylitis (radiographic axial spondyloarthritis): 5-year results from BE AGILE (phase 2b) and its open-label extension.
    RMD Open · 2025 · PMID 39890205 · NCT03355573

Hidradenitis Suppurativa (8)

  • Bimekizumab efficacy using IHS4 outcomes in hidradenitis suppurativa: Results from BE HEARD I and II.
    J Eur Acad Dermatol Venereol · 2026 · PMID 41689425 · NCT04242498
  • Bimekizumab Impact on Patient-Reported Outcomes in Patients with Moderate to Severe Hidradenitis Suppurativa: Pooled 48-Week Results from BE HEARD I&II.
    Dermatol Ther (Heidelb) · 2025 · PMID 40652434 · NCT04242446
  • Psychometric validation and interpretation thresholds of the Hidradenitis Suppurativa Quality of Life (HiSQOL©) questionnaire using pooled data from the phase III BE HEARD I & II trials of bimekizumab in hidradenitis suppurativa.
    Br J Dermatol · 2025 · PMID 40172122 · NCT04242446
  • Hidradenitis Suppurativa Symptom Daily Diary (HSSDD) and Questionnaire (HSSQ): Psychometric Validation and Interpretation Threshold Derivation Using Phase 3 Study Data.
    Dermatol Ther (Heidelb) · 2025 · PMID 40153232 · NCT04242446
  • Bimekizumab Pain Outcomes in Patients with Hidradenitis Suppurativa: Pooled 48-Week Results from BE HEARD I&II Phase 3 Randomized Clinical Trials.
    Pain Ther · 2025 · PMID 41107641 · NCT04242446

Axial Spondyloarthritis (4)

  • Improved Pain, Morning Stiffness, and Fatigue With Bimekizumab in Axial Spondyloarthritis: Results From the Phase III BE MOBILE Studies.
    J Rheumatol · 2025 · PMID 39406403 · NCT03928704
  • The Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) scale in patients with axial spondyloarthritis: psychometric properties and clinically meaningful thresholds for interpretation.
    J Patient Rep Outcomes · 2024 · PMID 39133438 · NCT03928704
  • Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies.
    Ann Rheum Dis · 2024 · PMID 37793792 · NCT03928704
  • Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials.
    Ann Rheum Dis · 2023 · PMID 36649967 · NCT03928704

Arthritis, Rheumatoid (1)

  • Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study.
    Ann Rheum Dis · 2020 · PMID 31177099 · NCT02430909

Publications by journal

Trial-results highlights

In the BE VIVID (NCT03370133) trial for psoriasis, at Week 16, bimekizumab 320 mg Q4W achieved a Psoriasis Area and Severity Index 90 (PASI90) response in 85.0% of participants, compared to 4.8% on placebo and 49.7% on ustekinumab. An Investigator's Global Assessment (IGA) response (clear or almost clear with at least a 2-category improvement from baseline) was reported in 84.1% of participants on bimekizumab 320 mg Q4W, versus 4.8% on placebo and 53.4% on ustekinumab. In the BE READY (NCT03410992) trial, 90.8% of participants on bimekizumab 320 mg Q4W achieved PASI90 response at Week 16, compared to 1.2% on placebo. An IGA response was observed in 92.6% of participants on bimekizumab 320 mg Q4W, versus 1.2% on placebo. The BE SURE (NCT03412747) trial reported that 86.2% of participants receiving bimekizumab 320 mg Q4W + bimekizumab 320 mg Q4W/Q8W achieved PASI90 response at Week 16, compared to 47.2% on adalimumab. For IGA response, 85.3% of participants on bimekizumab 320 mg Q4W + bimekizumab 320 mg Q4W/Q8W achieved the endpoint, versus 57.2% on adalimumab.

For complete skin clearance, the BE RADIANT (NCT03536884) trial showed that 61.7% of participants on bimekizumab 320 mg Q4W achieved a Psoriasis Area and Severity Index 100 (PASI100) response at Week 16, while 48.9% of participants on secukinumab 300 mg Q4W achieved this response. Regarding safety, the BE BRIGHT (NCT03598790) trial reported the number of treatment-emergent adverse events (TEAEs) per 100 subject-years:

  • Cohort A: Bimekizumab 320 mg Q4W: 179.68 new events
  • Cohort A: Bimekizumab 320 mg Q8W: 97.83 new events
  • Cohort A: Group A Bimekizumab 320 mg Q8W: 79.02 new events
  • Cohort A: Group B Bimekizumab 320 mg Q4W/Q8W: 73.78 new events
  • Cohort A: Group B Bimekizumab 320 mg Q8W: 77.11 new events
  • Cohort B: EP Bimekizumab Total: 328.25 new events

All values are sourced from primary registry reporting, and individual papers should be consulted for clinical decisions.

All Bimekizumab publications (78)

2026 (9 papers)

  1. Bimekizumab efficacy using IHS4 outcomes in hidradenitis suppurativa: Results from BE HEARD I and II.
    Tzellos T, Giamarellos-Bourboulis EJ, van Straalen KR, et al. · J Eur Acad Dermatol Venereol · 2026 · Trial result
    PubMed: PMID 41689425 · NCT04242498 (BE HEARD II) · Hidradenitis Suppurativa
  2. Bimekizumab Efficacy and Safety in Patients with Psoriatic Arthritis with Substantial Skin and Nail Psoriasis to 1 Year.
    Thaçi D, Asahina A, Boehncke WH, et al. · Dermatol Ther (Heidelb) · 2026 · Trial result
    PubMed: PMID 41381988 · NCT04009499 (BE VITAL) · Arthritis, Psoriatic
  3. Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison.
    Mease PJ, Warren RB, Nash P, et al. · Rheumatol Ther · 2026 · Trial result
    PubMed: PMID 38446397 · NCT03896581 (BE COMPLETE) · Arthritis, Psoriatic
  4. Bimekizumab long-term response in psoriasis: Mechanistic insights into efficacy level and durability.
    Krueger JG, Cutcutache I, Lebwohl M, et al. · J Allergy Clin Immunol · 2026 · Trial result
    PubMed: PMID 41580158 · NCT03370133 (BE VIVID) · Psoriasis
  5. Bimekizumab efficacy in scalp, nail and palmoplantar psoriasis versus comparators and over 4 years.
    Gisondi P, Elewski B, Pinter A, et al. · J Dermatolog Treat · 2026 · Trial result
    PubMed: PMID 41800601 · NCT03536884 (BE RADIANT) · Psoriasis
  6. Bimekizumab Impact on Patient-Reported Outcomes in Plaque Psoriasis: 4-Year Results from BE SURE, BE VIVID, BE READY, and BE BRIGHT.
    Armstrong A, Papp KA, Lebwohl M, et al. · Dermatol Ther (Heidelb) · 2026 · Trial result
    PubMed: PMID 41359217 · NCT03410992 (BE READY) · Psoriasis
  7. Bimekizumab longer-term safety profile in adult patients with axial spondyloarthritis or psoriatic arthritis: an updated analysis of six phase IIb/III clinical studies.
    Mease PJ, Merola JF, Magrey M, et al. · RMD Open · 2026 · Derived
    PubMed: PMID 41807031 · NCT03355573 (BE AGILE 2) · Spondylitis, Ankylosing
  8. Bimekizumab safety and efficacy in patients with psoriatic arthritis: 3-year results from two phase 3 studies.
    Gossec L, Coates LC, Landewé RBM, et al. · Rheumatology (Oxford) · 2026 · Derived
    PubMed: PMID 41838419 · NCT03896581 (BE COMPLETE) · Arthritis, Psoriatic
  9. Three-Year Patient-Reported Outcomes From Bimekizumab for Plaque Psoriasis: The BE RADIANT Randomized Clinical Trial With Open-Label Extension.
    Augustin M, Feldman SR, Warren RB, et al. · JAMA Dermatol · 2026 · Derived
    PubMed: PMID 41706476 · NCT03536884 (BE RADIANT) · Psoriasis

2025 (21 papers)

  1. Bimekizumab Efficacy in Psoriasis by Subgroups: Post Hoc Analysis of Phase 3/3b Clinical Trials.
    Strober B, Boehncke WH, Krueger JG, et al. · Dermatol Ther (Heidelb) · 2025 · Trial result
    PubMed: PMID 41060492 · NCT03598790 (BE BRIGHT) · Psoriasis
  2. Bimekizumab Impact on Patient-Reported Outcomes in Patients with Moderate to Severe Hidradenitis Suppurativa: Pooled 48-Week Results from BE HEARD I&II.
    Shi VY, Ingram JR, Lev-Tov H, et al. · Dermatol Ther (Heidelb) · 2025 · Trial result
    PubMed: PMID 40652434 · NCT04242446 (BE HEARD I) · Hidradenitis Suppurativa
  3. Single-Injection Options for Administering a 320 mg Dose of Bimekizumab: 2 mL Safety Syringe and Auto-injector.
    Sebastian M, Bagel J, Hoepken B, et al. · Dermatol Ther (Heidelb) · 2025 · Trial result
    PubMed: PMID 40156698 · NCT03766685 · Psoriasis
  4. Sustained resolution of enthesitis and peripheral arthritis over 104 weeks with bimekizumab in axial spondyloarthritis.
    Ramiro S, Poddubnyy D, Mease PJ, et al. · RMD Open · 2025 · Trial result
    PubMed: PMID 41125403 · NCT04436640 (BE MOVING) · Spondylitis, Ankylosing
  5. Efficacy and Safety of Bimekizumab in Japanese Patients with Generalised Pustular Psoriasis and Erythrodermic Psoriasis: 3-Year Results from BE BRIGHT, a Multicentre, Open-Label, Phase 3 Study.
    Okubo Y, Tada Y, Takahashi H, et al. · Dermatol Ther (Heidelb) · 2025 · Trial result
    PubMed: PMID 40788331 · NCT03598790 (BE BRIGHT) · Psoriasis
  6. Bimekizumab Efficacy in High-Impact Areas: Pooled 2-Year Analysis in Scalp, Nail, and Palmoplantar Psoriasis from Phase 3/3b Randomized Controlled Trials.
    Merola JF, Gottlieb AB, Pinter A, et al. · Dermatol Ther (Heidelb) · 2025 · Trial result
    PubMed: PMID 39578348 · NCT03598790 (BE BRIGHT) · Psoriasis
  7. Comparative Effectiveness of Bimekizumab and Risankizumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison.
    Mease PJ, Warren RB, Nash P, et al. · Rheumatol Ther · 2025 · Trial result
    PubMed: PMID 39120849 · NCT04009499 (BE VITAL) · Arthritis, Psoriatic
  8. Summary of Research: Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies.
    Mease PJ, Merola JF, Tanaka Y, et al. · Rheumatol Ther · 2025 · Trial result
    PubMed: PMID 40347389 · NCT03895203 (BE OPTIMAL) · Arthritis, Psoriatic
  9. Psychometric validation and interpretation thresholds of the Hidradenitis Suppurativa Quality of Life (HiSQOL©) questionnaire using pooled data from the phase III BE HEARD I & II trials of bimekizumab in hidradenitis suppurativa.
    Kirby JS, Thorlacius L, Lambert J, et al. · Br J Dermatol · 2025 · Trial result
    PubMed: PMID 40172122 · NCT04242446 (BE HEARD I) · Hidradenitis Suppurativa
  10. Hidradenitis Suppurativa Symptom Daily Diary (HSSDD) and Questionnaire (HSSQ): Psychometric Validation and Interpretation Threshold Derivation Using Phase 3 Study Data.
    Ingram JR, Lambert J, Ciaravino V, et al. · Dermatol Ther (Heidelb) · 2025 · Trial result
    PubMed: PMID 40153232 · NCT04242446 (BE HEARD I) · Hidradenitis Suppurativa
  11. Bimekizumab Pain Outcomes in Patients with Hidradenitis Suppurativa: Pooled 48-Week Results from BE HEARD I&II Phase 3 Randomized Clinical Trials.
    Ingram JR, Fujita H, Gottlieb AB, et al. · Pain Ther · 2025 · Trial result
    PubMed: PMID 41107641 · NCT04242446 (BE HEARD I) · Hidradenitis Suppurativa
  12. Bimekizumab efficacy and safety through 3 years in patients with moderate-to-severe plaque psoriasis: long-term results from the BE RADIANT phase IIIb trial open-label extension period.
    Warren RB, Lebwohl M, Thaçi D, et al. · Br J Dermatol · 2025 · Derived
    PubMed: PMID 39862230 · NCT03536884 (BE RADIANT) · Psoriasis
  13. An evaluation of bimekizumab for the treatment of hidradenitis suppurativa.
    Skrzypczak T, Skrzypczak A, Matusiak Ł, et al. · Expert Opin Biol Ther · 2025 · Derived
    PubMed: PMID 40524676 · NCT04901195 (BE HEARD EXT) · Hidradenitis Suppurativa
  14. Improved Pain, Morning Stiffness, and Fatigue With Bimekizumab in Axial Spondyloarthritis: Results From the Phase III BE MOBILE Studies.
    Navarro-Compán V, Rudwaleit M, Dubreuil M, et al. · J Rheumatol · 2025 · Derived
    PubMed: PMID 39406403 · NCT03928704 (BE MOBILE 1) · Axial Spondyloarthritis
  15. Bimekizumab Complete Clearance of Both Skin and Nail Psoriasis: Comparative Efficacy in Phase III/IIIb Studies.
    Merola JF, Warren RB, Thaçi D, et al. · Am J Clin Dermatol · 2025 · Derived
    PubMed: PMID 40886218 · NCT03598790 (BE BRIGHT) · Psoriasis
  16. Comparative Effectiveness of Bimekizumab and Ustekinumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison.
    Mease PJ, Warren RB, Nash P, et al. · Rheumatol Ther · 2025 · Derived
    PubMed: PMID 39120848 · NCT03896581 (BE COMPLETE) · Arthritis, Psoriatic
  17. Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies.
    Mease PJ, Merola JF, Tanaka Y, et al. · Rheumatol Ther · 2025 · Derived
    PubMed: PMID 39215949 · NCT04009499 (BE VITAL) · Arthritis, Psoriatic
  18. Long-term safety of bimekizumab in adult patients with axial spondyloarthritis or psoriatic arthritis: pooled results from integrated phase IIb/III clinical studies.
    Mease PJ, Gensler LS, Orbai AM, et al. · RMD Open · 2025 · Derived
    PubMed: PMID 40194794 · NCT04436640 (BE MOVING) · Spondylitis, Ankylosing
  19. Sustained improvements in spinal pain, morning stiffness, fatigue, sleep, physical function and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: 2-year results from two phase 3 studies.
    Marzo-Ortega H, Navarro-Compan V, Dubreuil M, et al. · RMD Open · 2025 · Derived
    PubMed: PMID 41314667 · NCT03928743 (BE MOBILE 2) · Spondylitis, Ankylosing
  20. Effect of Bimekizumab on Patient-Reported Outcomes and Work Productivity in Patients With Psoriatic Arthritis: 1-Year Results From 2 Phase III Studies.
    Gladman DD, Mease PJ, Gossec L, et al. · J Rheumatol · 2025 · Derived
    PubMed: PMID 39892885 · NCT03895203 (BE OPTIMAL) · Arthritis, Psoriatic
  21. Long-term safety and sustained efficacy of bimekizumab in patients with ankylosing spondylitis (radiographic axial spondyloarthritis): 5-year results from BE AGILE (phase 2b) and its open-label extension.
    Deodhar A, Navarro-Compán V, Poddubnyy D, et al. · RMD Open · 2025 · Derived
    PubMed: PMID 39890205 · NCT03355573 (BE AGILE 2) · Spondylitis, Ankylosing

2024 (18 papers)

  1. Bimekizumab efficacy and safety in Korean patients with moderate to severe plaque psoriasis: A phase 3, randomized, placebo-controlled, double-blinded study.
    Youn SW, Jo SJ, Park CJ, et al. · J Dermatol · 2024 · Trial result
    PubMed: PMID 39328126 · NCT05020249
  2. Comparative Effectiveness of Bimekizumab and Guselkumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison.
    Warren RB, McInnes IB, Nash P, et al. · Rheumatol Ther · 2024 · Trial result
    PubMed: PMID 38488975 · NCT03896581 (BE COMPLETE) · Arthritis, Psoriatic
  3. Minimal Impact of the COVID-19 Pandemic on Disease Activity and Health-Related Quality of Life in Patients With Ankylosing Spondylitis Receiving Bimekizumab: Exploratory Analyses From a Phase 2b Open-Label Extension Study.
    Robinson PC, Machado PM, Haroon N, et al. · ACR Open Rheumatol · 2024 · Trial result
    PubMed: PMID 35833532 · NCT02963506 (BE AGILE) · Spondylitis, Ankylosing
  4. Association of clinical response criteria and disease activity levels with axial spondyloarthritis core domains: results from two phase 3 randomised studies, BE MOBILE 1 and 2.
    Navarro-Compán V, Ramiro S, Deodhar A, et al. · RMD Open · 2024 · Trial result
    PubMed: PMID 38599650 · NCT03928743 (BE MOBILE 2) · Spondylitis, Ankylosing
  5. Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trials.
    Lebwohl M, Merola JF, Strober B, et al. · J Am Acad Dermatol · 2024 · Trial result
    PubMed: PMID 38588819 · NCT03536884 (BE RADIANT) · Psoriasis
  6. Association of achieving clinical disease control criteria and patient-reported outcomes in bimekizumab-treated patients with active psoriatic arthritis: results from two phase III studies.
    Kristensen LE, Tillett W, Nash P, et al. · Ther Adv Musculoskelet Dis · 2024 · Trial result
    PubMed: PMID 39534481 · NCT03896581 (BE COMPLETE) · Arthritis, Psoriatic
  7. Effect of bimekizumab on patient-reported disease impact in patients with psoriatic arthritis: 1-year results from two phase 3 studies.
    Gossec L, Orbai AM, de Wit M, et al. · Rheumatology (Oxford) · 2024 · Trial result
    PubMed: PMID 38754125 · NCT04009499 (BE VITAL) · Arthritis, Psoriatic
  8. Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials.
    Gordon KB, Langley RG, Warren RB, et al. · Br J Dermatol · 2024 · Trial result
    PubMed: PMID 37950894 · NCT03598790 (BE BRIGHT) · Psoriasis
  9. Improved physical functioning, sleep, work productivity and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: results from two phase 3 studies.
    Dubreuil M, Navarro-Compán V, Boonen A, et al. · RMD Open · 2024 · Trial result
    PubMed: PMID 38834351 · NCT03928743 (BE MOBILE 2) · Spondylitis, Ankylosing
  10. The Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) scale in patients with axial spondyloarthritis: psychometric properties and clinically meaningful thresholds for interpretation.
    Cella D, de la Loge C, Fofana F, et al. · J Patient Rep Outcomes · 2024 · Trial result
    PubMed: PMID 39133438 · NCT03928704 (BE MOBILE 1) · Axial Spondyloarthritis
  11. Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials.
    Brown MA, Rudwaleit M, van Gaalen FA, et al. · Ann Rheum Dis · 2024 · Trial result
    PubMed: PMID 38977276 · NCT04436640 (BE MOVING) · Spondylitis, Ankylosing
  12. Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM), a Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Data from the BE VIVID and BE READY Phase 3 Trials.
    Warren RB, Gottlieb AB, Merola JF, et al. · Dermatol Ther (Heidelb) · 2024 · Derived
    PubMed: PMID 34260044 · NCT03410992 (BE READY) · Psoriasis
  13. Comparative Effectiveness of Bimekizumab in Psoriatic Arthritis: A Model-Based Meta-Analysis of American College of Rheumatology Response Criteria.
    Maloney A, Dua P, Ahmed GF, et al. · Clin Pharmacol Ther · 2024 · Derived
    PubMed: PMID 38073049 · NCT03896581 (BE COMPLETE) · Arthritis, Psoriatic
  14. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials.
    Kimball AB, Jemec GBE, Sayed CJ, et al. · Lancet · 2024 · Derived
    PubMed: PMID 38795716 · NCT04242498 (BE HEARD II) · Hidradenitis Suppurativa
  15. Bimekizumab provided rapid improvements in patient-reported symptoms and health-related quality of life in patients with active psoriatic arthritis: pooled 16-week results from two phase 3 studies.
    Husni ME, Mease PJ, Merola JF, et al. · RMD Open · 2024 · Derived
    PubMed: PMID 39313302 · NCT03895203 (BE OPTIMAL) · Arthritis, Psoriatic
  16. Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies.
    Baraliakos X, Deodhar A, van der Heijde D, et al. · Ann Rheum Dis · 2024 · Derived
    PubMed: PMID 37793792 · NCT03928704 (BE MOBILE 1) · Axial Spondyloarthritis
  17. Impact of bimekizumab and certolizumab pegol on efficacy, safety and osteoblastic activity in radiographic axial spondyloarthritis: results from a phase IIa, multicentre, randomised, double-blind, exploratory study with PET-CT imaging.
    Baraliakos X, de Jongh J, Poddubnyy D, et al. · Ther Adv Musculoskelet Dis · 2024 · Derived
    PubMed: PMID 39620046 · NCT03215277 · Spondylitis, Ankylosing
  18. Complete Skin Clearance is Associated with the Greatest Benefits to Health-Related Quality of Life and Perceived Symptoms for Patients with Psoriasis.
    Augustin M, Gottlieb AB, Lebwohl M, et al. · Dermatol Ther (Heidelb) · 2024 · Derived
    PubMed: PMID 39285121 · NCT03536884 (BE RADIANT) · Psoriasis

2023 (11 papers)

  1. Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials.
    van der Heijde D, Deodhar A, Baraliakos X, et al. · Ann Rheum Dis · 2023 · Trial result
    PubMed: PMID 36649967 · NCT03928704 (BE MOBILE 1) · Axial Spondyloarthritis
  2. Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial.
    Thaçi D, Vender R, de Rie MA, et al. · Br J Dermatol · 2023 · Trial result
    PubMed: PMID 36689515 · NCT03598790 (BE BRIGHT) · Psoriasis
  3. Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial.
    Strober B, Paul C, Blauvelt A, et al. · J Am Acad Dermatol · 2023 · Trial result
    PubMed: PMID 37182701 · NCT03536884 (BE RADIANT) · Psoriasis
  4. Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study.
    Ritchlin CT, Coates LC, McInnes IB, et al. · Ann Rheum Dis · 2023 · Trial result
    PubMed: PMID 37696588 · NCT03895203 (BE OPTIMAL) · Arthritis, Psoriatic
  5. Effect of bimekizumab on symptoms and impact of disease in patients with psoriatic arthritis over 3 years: results from BE ACTIVE.
    Mease PJ, Asahina A, Gladman DD, et al. · Rheumatology (Oxford) · 2023 · Trial result
    PubMed: PMID 35789257 · NCT03347110 (BE ACTIVE 2) · Arthritis, Psoriatic
  6. Bimekizumab Efficacy and Safety in Japanese Patients with Plaque Psoriasis in BE VIVID: A Phase 3, Ustekinumab and Placebo-Controlled Study.
    Asahina A, Okubo Y, Morita A, et al. · Dermatol Ther (Heidelb) · 2023 · Trial result
    PubMed: PMID 36648594 · NCT03370133 (BE VIVID) · Psoriasis
  7. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE).
    Merola JF, Landewé R, McInnes IB, et al. · Lancet · 2023 · Derived
    PubMed: PMID 36495881 · NCT03896581 (BE COMPLETE) · Arthritis, Psoriatic
  8. Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL).
    McInnes IB, Asahina A, Coates LC, et al. · Lancet · 2023 · Derived
    PubMed: PMID 36493791 · NCT03895203 (BE OPTIMAL) · Arthritis, Psoriatic
  9. Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials.
    Kokolakis G, Warren RB, Strober B, et al. · Br J Dermatol · 2023 · Derived
    PubMed: PMID 36751950 · NCT03370133 (BE VIVID) · Psoriasis
  10. First-in-Human Intrathoracic Implantation of Multidrug-Eluting Microdevices for In Situ Chemotherapeutic Sensitivity Testing as Proof of Concept in Nonsmall Cell Lung Cancer.
    Tsai LL, Phillips WW, Hung YP, et al. · Ann Surg · 2023 · Background
    PubMed: PMID 35129472 · NCT07352566 · Psoriasis
  11. Intratumoral drug-releasing microdevices allow in situ high-throughput pharmaco phenotyping in patients with gliomas.
    Peruzzi P, Dominas C, Fell G, et al. · Sci Transl Med · 2023 · Background
    PubMed: PMID 37672566 · NCT07352566 · Psoriasis

2022 (7 papers)

  1. Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double-blind multicentre study.
    Oliver R, Krueger JG, Glatt S, et al. · Br J Dermatol · 2022 · Trial result
    PubMed: PMID 34687214 · NCT03025542 · Psoriasis
  2. Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials.
    Gordon KB, Langley RG, Warren RB, et al. · JAMA Dermatol · 2022 · Trial result
    PubMed: PMID 35544084 · NCT02905006 (BE ABLE 1) · Psoriasis
  3. Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial.
    Glatt S, Jemec GBE, Forman S, et al. · JAMA Dermatol · 2022 · Trial result
    PubMed: PMID 34406364 · NCT03248531 · Hidradenitis Suppurativa
  4. Safety and Efficacy of Bimekizumab in Patients With Active Ankylosing Spondylitis: Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension Study.
    Baraliakos X, Deodhar A, Dougados M, et al. · Arthritis Rheumatol · 2022 · Trial result
    PubMed: PMID 35829672 · NCT03355573 (BE AGILE 2) · Spondylitis, Ankylosing
  5. Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension Study.
    Coates LC, McInnes IB, Merola JF, et al. · Arthritis Rheumatol · 2022 · Derived
    PubMed: PMID 35829656 · NCT03347110 (BE ACTIVE 2) · Arthritis, Psoriatic
  6. Bimekizumab Self-Injection Devices: Two Multicenter, Randomized, Open-Label Studies on Self-Administration by Patients With Psoriasis.
    Bagel J, Tatla D, Hellot S, et al. · J Drugs Dermatol · 2022 · Derived
    PubMed: PMID 35133113 · NCT03766685 · Psoriasis
  7. A multiplex implantable microdevice assay identifies synergistic combinations of cancer immunotherapies and conventional drugs.
    Tatarova Z, Blumberg DC, Korkola JE, et al. · Nat Biotechnol · 2022 · Background
    PubMed: PMID 35788566 · NCT07352566 · Psoriasis

2021 (8 papers)

  1. Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study.
    Blauvelt A, Papp KA, Merola JF, et al. · J Am Acad Dermatol · 2021 · Trial result
    PubMed: PMID 32473974 · NCT03010527 (BE ABLE 2) · Psoriasis
  2. Out of the shadow of interleukin-17A: the role of interleukin-17F and other interleukin-17 family cytokines in spondyloarthritis.
    Yeremenko N · Curr Opin Rheumatol · 2021 · Derived
    PubMed: PMID 34001692 · NCT03536884 (BE RADIANT) · Psoriasis
  3. Bimekizumab versus Adalimumab in Plaque Psoriasis.
    Warren RB, Blauvelt A, Bagel J, et al. · N Engl J Med · 2021 · Derived
    PubMed: PMID 33891379 · NCT03412747 (BE SURE) · Psoriasis
  4. Dose reduction of the new generation biologics (IL-17 and IL-23 inhibitors) in psoriasis: study protocol for an international, pragmatic, multicenter, randomized, controlled, non-inferiority study-the BeNeBio study.
    van der Schoot LS, van den Reek JMPA, Grine L, et al. · Trials · 2021 · Derived
    PubMed: PMID 34656148 · NCT04340076 (BeNeBio) · Psoriasis
  5. Bimekizumab versus Secukinumab in Plaque Psoriasis.
    Reich K, Warren RB, Lebwohl M, et al. · N Engl J Med · 2021 · Derived
    PubMed: PMID 33891380 · NCT03536884 (BE RADIANT) · Psoriasis
  6. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.
    Reich K, Papp KA, Blauvelt A, et al. · Lancet · 2021 · Derived
    PubMed: PMID 33549193 · NCT03370133 (BE VIVID) · Psoriasis
  7. Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM): A Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Reported Data from the BE RADIANT Phase 3b Trial.
    Gottlieb AB, Warren RB, Augustin M, et al. · Adv Ther · 2021 · Derived
    PubMed: PMID 34471992 · NCT03536884 (BE RADIANT) · Psoriasis
  8. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.
    Gordon KB, Foley P, Krueger JG, et al. · Lancet · 2021 · Derived
    PubMed: PMID 33549192 · NCT03410992 (BE READY) · Psoriasis

2020 (3 papers)

  1. Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study.
    van der Heijde D, Gensler LS, Deodhar A, et al. · Ann Rheum Dis · 2020 · Trial result
    PubMed: PMID 32253184 · NCT02963506 (BE AGILE) · Spondylitis, Ankylosing
  2. Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial.
    Ritchlin CT, Kavanaugh A, Merola JF, et al. · Lancet · 2020 · Derived
    PubMed: PMID 32035552 · NCT02969525 (BE ACTIVE) · Arthritis, Psoriatic
  3. Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study.
    Glatt S, Taylor PC, McInnes IB, et al. · Ann Rheum Dis · 2020 · Derived
    PubMed: PMID 31177099 · NCT02430909 · Arthritis, Rheumatoid

2016 (1 paper)

  1. An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors.
    Jonas O, Landry HM, Fuller JE, et al. · Sci Transl Med · 2016 · Background
    PubMed: PMID 25904741 · NCT07352566 · Psoriasis

Sources and methodology

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).